bpc-157

the contested repair peptide. strong animal data, thin human trials, huge community gravity.

tier A · healing · 200+ rodent · 0 RCTs

verdict

the contested repair peptide. 200+ rat studies with consistent tissue-repair signals. zero published controlled human RCTs in tendon or injury recovery.

if you're asking whether BPC-157 actually heals tendons — in rats, indisputably. across tendon, ligament, gut lining, and vascular tissue. the human record is a small interstitial-cystitis pilot, an n=2 IV safety pilot, an older phase 1 registry with no posted results, and a recruiting phase 2 hamstring-strain trial. no controlled human tendon or injury-recovery results have been published. extrapolating the rat angiogenesis mechanism to a torn rotator cuff is preclinical inference, not proven.

if you're asking about the gut and IBS angle — the preclinical signal in gut lining is among the strongest in the BPC-157 dataset. lifters with chronic gut issues often anecdotally describe relief. the interstitial-cystitis pilot is the closest controlled human signal there is. it's a hypothesis with rat data behind it, not a treatment with human RCT evidence behind it.

if you're asking about the regulatory state — the FDA pulled BPC-157 off 503A category 2 on April 22, 2026. PCAC reviews it July 23. the gray-market vendor channel continues operating; compounding pharmacies do not. supply and pricing for community users are mid-shift. the rat data is too consistent to dismiss. the regulatory direction is one-way from here until human trials change the conversation.

based on published evidence and disclosed clinical practice. not medical advice.

why A-tier

A-tier because the preclinical evidence is extraordinary and the community signal is persistent. Not S-tier because drug-grade human evidence does not exist, long-term human safety is not characterized, and the single-lab concentration matters. If independent controlled trials ever hold up, the tier can move. Until then, A is the ceiling.

the core tension

200+ animal papers, mostly from one research network. zero finished human RCTs for tendon or injury recovery. the molecule has more animal momentum than almost anything in the gray peptide market and less human proof than the culture implies.

what it is

A 15-amino-acid synthetic peptide. A fragment of a larger 'body protection compound' first isolated from human gastric juice in the 1990s. What vendors sell isn't a natural sequence. It's an engineered piece of the parent protein.

what it does

In animal models, BPC-157 shows tissue-repair signals across tendons, ligaments, gut lining, and vascular tissue. The proposed mechanism is angiogenesis. The molecule appears to accelerate new blood vessel formation at injury sites in preclinical models. Anti-inflammatory effects are also documented in rats.

origin

Predrag Sikiric's lab at the University of Zagreb, Croatia, found and characterized the molecule starting in the 1990s. The Sikiric lab has produced the bulk of the published research. Over 200 animal studies, virtually all positive. That single-source concentration is part of why the field is skeptical.

why researchers are interested

Lifters and athletes treat it like the folk hero of tendon and ligament injury recovery. The reports are everywhere, and the preclinical signal explains why the reputation stuck. The catch is still the catch: community trust is a datapoint, not a controlled trial.

does it work

In rats, indisputably. In humans, still unproven for tendon and injury recovery. The human record is a small interstitial-cystitis pilot, an n=2 IV safety pilot, an older phase 1 registry with no posted results, and a recruiting phase 2 hamstring-strain trial. No controlled human tendon or injury-recovery results have been published. The FDA pulled BPC-157 off 503A category 2 on April 22, 2026. PCAC reviews it on July 23. The rat data is too consistent to dismiss. Extrapolating it to achilles or shoulder repair remains preclinical inference, not controlled human evidence.

claims vs the data

heals tendon and ligament injuries faster than anything else — preclinical — dozens of rat tendon studies. no controlled human tendon or injury-recovery RCT yet.
cures leaky gut and IBS — overreach — rat ulcer models don't generalize to human IBS. Pliva phase II was abandoned.
fixes chronic injuries doctors gave up on — weak — anecdotal only. selection bias severe in reddit reports.
regrows nerve tissue — weak — one rat sciatic nerve study. no replication.
protects the brain from TBI — only in rats — rodent TBI models exist. zero human data.
gray-market vials are the same thing sikirić studies — partially true — sometimes. identity, purity, sterility, and concentration are the weak links in the research-vial market.
miracle healing peptide — overreach — works for specific mesenchymal tissue repair. not a miracle.
works for treatment-resistant interstitial cystitis — partially true — 2024 pilot (Lee, Walker, Ayadi): 12 women non-responsive to pentosan polysulfate, single intravesical injection of 10mg BPC-157. 10/12 reported 100% symptom resolution, 2/12 reported 80%. No adverse events. First real human efficacy signal for BPC-157 in any indication. But no control group, small sample, single site. Needs RCT replication before 'supported'.
BPC-157 human tendon healing is proven — weak — The tendon and connective-tissue animal literature is unusually consistent, but direct human tendon-healing trials remain the missing piece. The strongest honest claim is preclinical plausibility plus unusually strong community signal, not proven human tendon repair.

key facts

molecular formula: C₆₂H₉₈N₁₆O₂₂
molecular weight: 1419.53 g/mol
amino acids: 15
half-life: short (minutes IV)
type: pentadecapeptide
CAS: 137525-51-0
~200 published studies
~95% from one croatian lab
0 phase III trials
$1–2B cost to run them

frequently asked questions

What is BPC-157?

BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. It is sold as a research chemical and has no FDA-approved human use.

What does BPC-157 do?

BPC-157 has demonstrated wound-healing, tendon-repair, and anti-inflammatory effects across more than 200 preclinical studies, nearly all in rodent models. Community reports describe accelerated recovery from tendon, ligament, and joint injuries, though these are uncontrolled anecdotes, not trial data. Human evidence now includes one small uncontrolled interstitial-cystitis pilot and a tiny IV safety pilot, but no controlled human tendon or injury-recovery trial.

How is BPC-157 typically administered?

BPC-157 appears in subcutaneous, oral, nasal, and intravesical research contexts, depending on the study or market. There is no FDA-approved human dosing protocol, and the small interstitial-cystitis pilot cannot be extrapolated to injury-recovery use.

What are the side effects of BPC-157?

Community reports are notably clean. Users rarely report systemic side effects. Occasional injection-site soreness is the most cited adverse event. The small human pilots do not establish long-term safety, and product identity, sterility, purity, and route-specific safety remain live issues in the research-peptide market.

Is BPC-157 FDA approved?

No. BPC-157 is not FDA-approved for any indication and is sold as a research chemical. It is not a controlled substance in the US. Possession for research purposes is generally legal; human use outside clinical trials is unapproved.

How much does BPC-157 cost?

BPC-157 isn't a prescription drug and has no clinical retail price. On the research-chemical market it is inexpensive. Some wellness and hormone clinics have sold compounded injury-recovery packages, but that market context is not evidence of clinical efficacy.

related peptides

bpc+tb blend — the wolverine blend, BPC+TB in one vial
tb-500 — paired as the systemic half of wolverine
glow — contains BPC-157 as a component
klow — contains BPC-157 + GHK-Cu + TB-500 + KPV

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.